New psychoactive substances: a review and updates
- PMID: 33414905
- PMCID: PMC7750892
- DOI: 10.1177/2045125320967197
New psychoactive substances: a review and updates
Abstract
New psychoactive substances (NPS) are a heterogeneous group of substances. They are associated with a number of health and social harms on an individual and societal level. NPS toxicity and dependence syndromes are recognised in primary care, emergency departments, psychiatric inpatient and community care settings. One pragmatic classification system is to divide NPS into one of four groups: synthetic stimulants, synthetic cannabinoids, synthetic hallucinogens and synthetic depressants (which include synthetic opioids and benzodiazepines). We review these four classes of NPS, including their chemical structures, mechanism of action, modes of use, intended intoxicant effects, and their associated physical and mental health harms. The current challenges faced by laboratory testing for NPS are also explored, in the context of the diverse range of NPS currently available, rate of production and emergence of new substances, the different formulations, and methods of acquisition and distribution.
Keywords: NPS; laboratory testing; new psychoactive substances; synthetic cannabinoid receptor agonists; synthetic hallucinogens; synthetic opioids; synthetic stimulants.
© The Author(s), 2020.
Conflict of interest statement
Conflict of interest statement: The authors declare that there is no conflict of interest.
Similar articles
-
Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists.Arch Pharm Res. 2021 Apr;44(4):402-413. doi: 10.1007/s12272-021-01326-6. Epub 2021 Apr 2. Arch Pharm Res. 2021. PMID: 33811300 Review.
-
[New psychoactive substances in emergency medicine].Nervenarzt. 2024 Jan;95(1):28-34. doi: 10.1007/s00115-023-01602-4. Epub 2024 Jan 8. Nervenarzt. 2024. PMID: 38189941 Review. German.
-
New Psychoactive Substances: A Canadian perspective on emerging trends and challenges for the clinical laboratory.Clin Biochem. 2024 Dec;133-134:110810. doi: 10.1016/j.clinbiochem.2024.110810. Epub 2024 Aug 23. Clin Biochem. 2024. PMID: 39181179 Review.
-
New Psychoactive Substances and receding COVID-19 pandemic: really going back to "normal"?Acta Biomed. 2022 May 11;93(2):e2022186. doi: 10.23750/abm.v93i2.13008. Acta Biomed. 2022. PMID: 35545997 Free PMC article.
-
Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2013-2016: A Review.J Anal Toxicol. 2017 Sep 1;41(7):573-610. doi: 10.1093/jat/bkx031. J Anal Toxicol. 2017. PMID: 28459969 Review.
Cited by
-
New Psychoactive Substances: Awareness and Attitudes of Future Health Care Professionals in Serbia.Int J Environ Res Public Health. 2022 Nov 11;19(22):14877. doi: 10.3390/ijerph192214877. Int J Environ Res Public Health. 2022. PMID: 36429596 Free PMC article.
-
Understanding the Mechanisms of Action and Effects of Drugs of Abuse.Molecules. 2023 Jun 24;28(13):4969. doi: 10.3390/molecules28134969. Molecules. 2023. PMID: 37446631 Free PMC article. Review.
-
Knowledge and Use of Novel Psychoactive Substances in an Italian Sample with Substance Use Disorders.Int J Environ Res Public Health. 2022 Jan 14;19(2):915. doi: 10.3390/ijerph19020915. Int J Environ Res Public Health. 2022. PMID: 35055743 Free PMC article.
-
Rapid Targeted Method of Detecting Abused Piperazine Designer Drugs.J Clin Med. 2021 Dec 12;10(24):5813. doi: 10.3390/jcm10245813. J Clin Med. 2021. PMID: 34945109 Free PMC article.
-
Characterization of URB Series Synthetic Cannabinoids by HRMS and UHPLC-MS/MS.Pharmaceuticals (Basel). 2023 Jan 29;16(2):201. doi: 10.3390/ph16020201. Pharmaceuticals (Basel). 2023. PMID: 37259350 Free PMC article.
References
-
- Peacock A, Bruno R, Gisev N, et al. New psychoactive substances: challenges for drug surveillance, control, and public health responses. Lancet 2019; 394: 1668–1684. - PubMed
-
- Soussan C, Kjellgren A. The users of novel psychoactive substances: online survey about their characteristics, attitudes and motivations. Int J Drug Policy 2016; 32: 77–84. - PubMed
-
- O’Hagan A, McCormack S. To what extent has the United Kingdom law on psychoactive substances been successful? Forensic Res Criminol 2019; 7: 176–183.
-
- Batisse A, Eiden C, Peyriere H, et al. Use of new psychoactive substances to mimic prescription drugs: the trend in France. Neurotoxicology 2020; 79: 20–24. - PubMed
Publication types
LinkOut - more resources
Full Text Sources